uridine has been researched along with sq-641 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franzblau, SG; Kurosu, M; Mitachi, K; Siricilla, S; Wan, B | 1 |
| Chopra, S; Dasgupta, A; De Groote, MA; Soni, I | 1 |
| Bogatcheva, E; Einck, L; Guerrant, RL; Kolling, GL; Moore, JH; Nikonenko, B; Phipps, AJ; Protopopova, M; Shin, JH; van Opstal, E; Warren, CA | 1 |
| Baráth, P; Barrio, MB; Huszár, S; Lagrange, S; Leblanc, V; Mikušová, K; Mizrahi, V; Nacy, CA; Polčicová, A; Singh, V | 1 |
| Karkara, BB; Kumar, A; Panda, G | 1 |
2 review(s) available for uridine and sq-641
| Article | Year |
|---|---|
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.
Topics: Adamantane; Aminopyridines; Anti-Bacterial Agents; Azepines; Benzamides; Clinical Trials as Topic; Diarylquinolines; Drug Discovery; Ethylenediamines; Fluoroquinolones; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Piperazines; Spiro Compounds; Thiazines; Tigecycline; Uridine | 2016 |
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Topics: Adamantane; Animals; Antitubercular Agents; DNA Gyrase; Drug Development; Enzyme Inhibitors; Humans; Isonicotinic Acids; Mycobacterium tuberculosis; Oxazolidinones; Piperidines; Pyrroles; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant; Uridine | 2021 |
3 other study(ies) available for uridine and sq-641
| Article | Year |
|---|---|
Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.
Topics: Aminoglycosides; Antitubercular Agents; Bacterial Proteins; Caprolactam; DNA-Directed RNA Polymerases; Drug Synergism; Enzyme Inhibitors; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxygen; Structure-Activity Relationship; Transferases; Transferases (Other Substituted Phosphate Groups); Uridine | 2015 |
Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.
Topics: Administration, Oral; Aminoglycosides; Animals; Anti-Bacterial Agents; Bacterial Shedding; Bacterial Toxins; Clostridioides difficile; Disease Models, Animal; Enterocolitis, Pseudomembranous; Feces; Male; Mice, Inbred C57BL; Severity of Illness Index; Survival Analysis; Treatment Outcome; Uridine | 2016 |
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Evaluation, Preclinical; Gene Expression Regulation, Bacterial; Gene Silencing; Macrophages; Microbial Sensitivity Tests; Molecular Targeted Therapy; Mycobacterium smegmatis; Mycobacterium tuberculosis; Radiometry; Transferases; Transferases (Other Substituted Phosphate Groups); Tuberculosis; Tunicamycin; Uridine | 2017 |